AI Proteins is a company.
AI Proteins has raised $18.0M across 1 funding round.
Key people at AI Proteins.
AI Proteins has raised $18.0M in total across 1 funding round.
AI Proteins has raised $18.0M in total across 1 funding round.
AI Proteins's investors include Cobro Ventures.
Key people at AI Proteins.
AI Proteins is a Boston-based biotech company that designs entirely new de novo miniproteins using AI, synthetic biology, and robotics for drug discovery and therapeutics.[2][3][5] It targets conditions like inflammation, metabolic diseases, and cancer by creating synthetic proteins optimized for oral delivery, high specificity, stability, and low cost, serving pharmaceutical clients and advancing internal programs.[1][3] The company solves the limitations of natural proteins—such as poor tissue penetration, immunogenicity, and evolutionary constraints—by engineering modular, purpose-built miniproteins from first principles, accelerating lead candidate generation at scale.[3][4][5] Recent momentum includes a $41.5M Series A in November 2025 and a Bristol Myers Squibb collaboration worth up to $400M, with in vivo proof-of-concept across 150+ targets.[3][4]
AI Proteins emerged from advances in generative AI and high-throughput platforms to re-imagine protein therapeutics, unconstrained by natural evolution.[2][3][5] While specific founders are not detailed in available sources, the company is headquartered in Boston and has quickly gained traction through its novel de novo design approach, validating scalability via internal programs and partnerships.[3][4] Pivotal moments include the December 2024 Bristol Myers Squibb research collaboration and option agreement, alongside achieving in vivo proof-of-concept for multiple molecules, culminating in the $41.5M Series A led by Mission BioCapital and Santé Ventures in November 2025.[3][4]
AI Proteins rides the convergence of generative AI, synthetic biology, and automation in biotech, enabling a new class of programmable therapeutics amid rising demand for precise, scalable biologics.[3][5] Timing is ideal post-2024 AI breakthroughs, as high-throughput platforms address biotech's productivity crisis—traditional proteins face immunogenicity and manufacturing hurdles, while miniproteins offer safer, cheaper alternatives.[1][4] Market forces like pharma's push for novel modalities (e.g., multispecifics) and partnerships like Bristol Myers Squibb favor it, influencing the ecosystem by unlocking de novo design for non-therapeutic fields and setting a scalable blueprint for AI-driven drug discovery.[3][4]
AI Proteins is positioned to pioneer de novo miniproteins as the next therapeutic frontier, with Series A funds advancing clinical candidates and the BMS deal potentially yielding milestones up to $400M.[3][4] Trends like AI model refinement from proprietary data, robotics scaling, and hub-and-spoke expansion will accelerate multi-program progress across therapeutics, diagnostics, and agriculture.[4][5] Its influence may evolve by commoditizing protein design, powering pharma pipelines and spinouts, ultimately delivering oral, patient-tuned biologics that redefine biotech efficiency—transforming "artisanal science" into industrial precision.[3]
AI Proteins has raised $18.0M across 1 funding round. Most recently, it raised $18.0M Seed in January 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2022 | $18.0M Seed | Cobro Ventures |
